2025年ESC/EAS血脂管理指南焦点更新解读及中国临床实践建议
DOI:
作者:
作者单位:

(宁波大学附属第一医院,浙江省宁波市 315020)

作者简介:

陈泓臻,医学硕士,医师,研究方向为动脉粥样硬化性心血管疾病,E-mail:chhzh123456@outlook.com。

通讯作者:

基金项目:

宁波市重点技术研发项目(2022Z149);浙江省动脉粥样硬化疾病精准医学研究重点实验室开放课题(2022E10026)


Interpretation of the 2025 ESC/EAS focused update of the dyslipidaemia guidelines and recommendations for clinical practice in China
Author:
Affiliation:

The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315020, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    年ESC/EAS发布的血脂管理指南要点更新,在保留2019版指南核心框架的基础上,结合近年来的重要临床研究进展、新药获批上市及新适应证拓展、风险评估工具的临床应用,对指南内容作出了修订与完善。核心亮点包括:进一步明确采用SCORE2/SCORE2-OP作为心血管绝对风险评估工具;将贝派地酸及依维苏单抗纳入临床用药选择范围;强调脂蛋白(a)[Lp(a)]的测定价值与临床意义;对急性冠脉综合征(ACS)住院期的早期降脂策略提出了更明确的指导建议。该文基于本次指南要点更新和相关述评内容,归纳解读指南的主要修订内容,并结合中国临床实际提出可行性实践建议,旨在帮助国内临床同道准确理解本次更新的核心要点、优化血脂异常诊疗路径,推动该指南在国内的落地与有效实施。

    Abstract:

    The updated key points of the blood lipid management guidelines released by ESC/EAS in 2025 have been revised and improved based on the retention of the core framework of the 2019 version of the guidelines, combined with important clinical research progress in recent years, new drug approvals and indications expansion, and clinical application of risk assessment tools. The core highlights include:further clarification on the use of SCORE2/SCORE2-OP as a cardiovascular absolute risk assessment tool; including bempedoic acid and evinacumab in clinical therapeutic options; emphasizing the value and clinical significance of measuring lipoprotein (a) [Lp (a)]; and providing clear recommendations for early lipid-lowering strategies during hospitalization for acute coronary syndrome (ACS). This article summarizes and interprets the main revisions of the guidelines based on the updated key points and related reviews, and proposes feasible practical suggestions in combination with the actual clinical situation in China. The aim is to help domestic clinical colleagues accurately understand the core points of this update, optimize the diagnosis and treatment path of dyslipidemia, and promote the implementation of the guidelines in China.

    参考文献
    相似文献
    引证文献
引用本文

陈泓臻,胡颖楚,林少沂,陈晓敏.2025年ESC/EAS血脂管理指南焦点更新解读及中国临床实践建议[J].中国动脉硬化杂志,2026,34(10):935~941.

复制
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2026-03-31
  • 最后修改日期:2026-07-12
  • 录用日期:
  • 在线发布日期: 2026-11-19